Filter Results

Locations

Study status

(for at least one location)

Gender

Age

Study phase

What is this?
During the early phases (phases 1 and 2), researchers assess safety, side effects, optimal dosages and risks/benefits. In the later phase (phase 3), researchers study whether the treatment works better than the current standard therapy. They also compare the safety of the new treatment with that of current treatments. Phase 3 trials include large numbers of people to make sure that the result is valid. There are also less common very early (phase 0) and later (phase 4) phases. Phase 0 trials are small trials that help researchers decide if a new agent should be tested in a phase 1 trial. Phase 4 trials look at long-term safety and effectiveness, after a new treatment has been approved and is on the market.

Search Results 1-10 of 13 for

  • Results filtered:
  • Study status: Open/Status Unknown
Edit search filters
  1. A Study Evaluating Temozolomide vs. Temozolomide and Olaparib for Advanced Pheochromocytoma and Paraganglioma

    Rochester, MN

  2. A Study to Evaluate Cabozantinib S-malate in Treating Patients with Neuroendocrine Tumors that are Locally Advanced, Metastatic, or Cannot Be Removed by Surgery and Previously Treated with Everolimus

    Jacksonville, FL, Rochester, MN, Scottsdale/Phoenix, AZ

  3. A Study to Test the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) with One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors

    Eau Claire, WI, Scottsdale/Phoenix, AZ, Rochester, MN

  4. A Trial to Assess Effectiveness and Safety of Octreotide Subcutaneous Depot in Patients With GEP-NET

    Scottsdale/Phoenix, AZ, Jacksonville, FL, Rochester, MN

  5. Testing the Use of Chemotherapy After Surgery for High-Risk Pancreatic Neuroendocrine Tumors

    Scottsdale/Phoenix, AZ, Rochester, MN

  6. A Study to Evaluate Triapine Combined with Lutetium Lu 177 Dotatate for Gastroenteropancreatic Neuroendocrine Tumors

    Scottsdale/Phoenix, AZ, Jacksonville, FL, Rochester, MN

  7. Sapanisertib in Treating Patients With Metastatic or Refractory Pancreatic Neuroendocrine Tumor That Cannot Be Removed by Surgery

    Rochester, MN, Scottsdale/Phoenix, AZ, Rochester, MN

  8. Lutetium 177Lu-Edotreotide Versus Best Standard of Care in Well-differentiated Aggressive Grade-2 and Grade-3 GastroEnteroPancreatic NeuroEndocrine Tumors (GEP-NETs) - COMPOSE (COMPOSE)

    Rochester, MN

  9. A Study of AMG 757 in Participants With Neuroendocrine Prostate Cancer

    Scottsdale/Phoenix, AZ

  10. Study to Evaluate the Efficacy and Safety of Lutathera in Patients with Grade 2 and Grade 3 Advanced GEP-NET

    Rochester, MN

.

Mayo Clinic Footer